Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
BridgeBio Oncology Therapeutics Inc.
Market Cap
$280.37M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$281.54M
Net Profit Margin
0.00%
TTM Avg
-6.08%
3Y Avg
-1303.66%
5Y Avg
-1073.20%
Market Cap
$282.64M
Net Profit Margin
-103.29%
TTM Avg
-83.69%
3Y Avg
-107.92%
5Y Avg
-85.90%
Market Cap
$284.31M
Net Profit Margin
-38.13%
TTM Avg
-18.76%
3Y Avg
-107.01%
5Y Avg
-249.44%
Market Cap
$285.42M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-348.45%
5Y Avg
-232.30%
Market Cap
$285.55M
Net Profit Margin
-246.42%
TTM Avg
611.54%
3Y Avg
-783.13%
5Y Avg
-1134.34%
Market Cap
$288.79M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$271.81M
Net Profit Margin
-127.41%
TTM Avg
-55.77%
3Y Avg
-26.94%
5Y Avg
-14.34%
Market Cap
$270.80M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $280.37M | 0.00% | 0.00% | 0.00% | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | 0.00% | -6.08% | -1303.66% | -1073.20% |
| Standard BioTools Inc. (LAB)vs › | $282.64M | -103.29% | -83.69% | -107.92% | -85.90% |
| Aurora Cannabis Inc. (ACB)vs › | $284.31M | -38.13% | -18.76% | -107.01% | -249.44% |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.42M | 0.00% | 0.00% | -348.45% | -232.30% |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | -246.42% | 611.54% | -783.13% | -1134.34% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $288.79M | 0.00% | 0.00% | 0.00% | 0.00% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | -127.41% | -55.77% | -26.94% | -14.34% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | 0.00% | 0.00% | 0.00% | 0.00% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $292.59M | -145.12% | -145.12% | -145.12% | -145.12% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2022-12-31 | 0.00% |
